Multimodal, broadly neutralizing antibodies against SARS-CoV-2 identified by high-throughput native pairing of BCRs from bulk B cells

Gladys J Keitany,Benjamin E R Rubin,Meghan E Garrett,Andrea Musa,Jeff Tracy,Yu Liang,Peter Ebert,Amanda J Moore,Jonathan Guan,Erica Eggers,Ninnia Lescano,Ryan Brown,Adria Carbo,Hussein Al-Asadi,Travers Ching,Austin Day,Rebecca Harris,Charles Linkem,Dimitry Popov,Courtney Wilkins,Lianqu Li,Jiao Wang,Chuanxin Liu,Li Chen,Jennifer N Dines,Caroline Atyeo,Galit Alter,Lance Baldo,Anna Sherwood,Bryan Howie,Mark Klinger,Erik Yusko,Harlan S Robins,Sharon Benzeno,Amy E Gilbert

DOI: https://doi.org/10.1016/j.chembiol.2023.07.011

2023-11-16

Abstract:TruAB Discovery is an approach that integrates cellular immunology, high-throughput immunosequencing, bioinformatics, and computational biology in order to discover naturally occurring human antibodies for prophylactic or therapeutic use. We adapted our previously described pairSEQ technology to pair B cell receptor heavy and light chains of SARS-CoV-2 spike protein-binding antibodies derived from enriched antigen-specific memory B cells and bulk antibody-secreting cells. We identified approximately 60,000 productive, in-frame, paired antibody sequences, from which 2,093 antibodies were selected for functional evaluation based on abundance, isotype and patterns of somatic hypermutation. The exceptionally diverse antibodies included RBD-binders with broad neutralizing activity against SARS-CoV-2 variants, and S2-binders with broad specificity against betacoronaviruses and the ability to block membrane fusion. A subset of these RBD- and S2-binding antibodies demonstrated robust protection against challenge in hamster and mouse models. This high-throughput approach can accelerate discovery of diverse, multifunctional antibodies against any target of interest.